Výsledky vyhledávání - "Lauryn S. Bracken"

Akademický článek

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Publikováno v: Cell Reports, Vol 5, Iss 4, Pp 1047-1059 (2013)

To design rational therapies for JAK2-driven hematological malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2. In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathways were

Externí odkaz: https://doaj.org/article/038b13b134c84948ae45ebf210800b23

Zobrazit plný text záznamu

Supplementary Materials and Methods, Supplementary Tables 1 through 9, and Supplementary Figures 1 through 8 from Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Autor: Richard B. Lock, Malcolm A. Smith, Peter J. Houghton, Stephen P. Hunger, Mignon L. Loh, Cheryl L. Willman, Charles G. Mullighan, Catherine A. Billups, Raushan T. Kurmasheva, Kathryn G. Roberts, Philipp A. Dietrich, Kathryn Evans, I-Ming Chen, Hernan Carol, Keith C.S. Sia, Richard C. Harvey, Lauryn S. Bracken, Santi Suryani

Supplementary Materials and Methods. Supplementary Table S1. QC of Affymetrix U133_Plus_2.0 Data. Supplementary Table S2. Summary of the Objective Response Measure (ORM) scoring methodology. Supplementary Table S3. Correlation of xenograft with paren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3368725252e9fbbf2a94692c84a5b21
https://doi.org/10.1158/1535-7163.22503796

Zobrazit plný text záznamu

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Autor: Kathryn Evans, Raushan T. Kurmasheva, William R. Wilson, Donya Moradi Manesh, Ashlee Hedrick, Catherine A. Billups, Cara E. Toscan, Hernan Carol, Peter J. Houghton, Glenn M. Marshall, Jennifer Richmond, Rosemary Sutton, Lauryn S. Bracken, Jad El-Hoss, Malcolm A. Smith, Richard B. Lock

Publikováno v: Blood. 126:1193-1202

PR-104, a phosphate ester of the nitrogen mustard prodrug PR-104A, has shown evidence of efficacy in adult leukemia clinical trials. Originally designed to target hypoxic cells, PR-104A is independently activated by aldo-keto-reductase 1C3 (AKR1C3).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faefe87e0309154c0ba137f5e67fddf1
https://doi.org/10.1182/blood-2014-12-618900

Zobrazit plný text záznamu

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Autor: Kathryn Evans, Raushan T. Kurmasheva, Cheryl L. Willman, Lauryn S. Bracken, Richard B. Lock, Hernan Carol, Peter J. Houghton, Keith C.S. Sia, Mignon L. Loh, Charles G. Mullighan, Santi Suryani, Stephen P. Hunger, Catherine A. Billups, Kathryn G. Roberts, Malcolm A. Smith, I-Ming Chen, Richard C. Harvey, Philipp A. Dietrich

Publikováno v: Molecular Cancer Therapeutics. 14:364-374

Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18f00a78f238c9a1a9141a7e6dccf9d7
https://doi.org/10.1158/1535-7163.mct-14-0647

Zobrazit plný text záznamu

Up-regulation of survivin during immortalization of human myofibroblasts is linked to repression of tumor suppressor p16(INK4a) protein and confers resistance to oxidative stress

Autor: Jun Yuan, Ning Xu, Karen L. MacKenzie, Rosemary O'Brien, Richard B. Lock, Carlotta Petti, Chen Yang, Tao Liu, Chin-Yi Kan, Michelle F. Maritz, Lauryn S. Bracken

Publikováno v: The Journal of biological chemistry. 288(17)

Survivin is an essential component of the chromosomal passenger complex and a member of the inhibitor of apoptosis family. It is expressed at high levels in a large variety of malignancies, where it has been implicated in drug resistance. It was also

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f68768501bf0129078d566261f97e666
https://pubmed.ncbi.nlm.nih.gov/23449974

Zobrazit plný text záznamu

Abstract 3276: Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program

Autor: Jennifer Richmond, Lauryn S. Bracken, Raushan T. Kurmasheva, Kathryn Evans, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock, Alissa Robbins, Santi Suryani

Publikováno v: Cancer Research. 75:3276-3276

Targeting the apoptosis pathway with BH3 mimetics such as ABT-263 (navitoclax) and ABT-199 is an appealing strategy for cancer therapy. While the Bcl-2/Bcl-w/Bcl-xL inhibitor navitoclax has shown promising activity in adults with lymphoid malignancie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4661e25be58a22a38a5b9f9fbb390890
https://doi.org/10.1158/1538-7445.am2015-3276

Zobrazit plný text záznamu

Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia

Autor: Richard B. Lock, Peter J. Houghton, Raushan T. Kurmasheva, Hernan Carol, Santi Suryani, Keith C.S. Sia, Malcolm A. Smith, Kathryn Evans, Lauryn S. Bracken

Publikováno v: Blood. 120:3562-3562

Abstract 3562 Relapsed/refractory pediatric acute lymphoblastic leukemia (ALL) remains a continuing challenge to treat with currently available therapies, and new treatments are urgently required for the management of these high-risk cases. Activatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e7a9824812549e01eb0f06cac6a95b0
https://doi.org/10.1182/blood.v120.21.3562.3562

Zobrazit plný text záznamu

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Publikováno v: Cell Reports
Cell Reports, Vol 5, Iss 4, Pp 1047-1059 (2013)
Cell reports

Summary To design rational therapies for JAK2-driven hematological malignancies, we functionally dissected the key survival pathways downstream of hyperactive JAK2. In tumors driven by mutant JAK2, Stat1, Stat3, Stat5, and the Pi3k and Mek/Erk pathwa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56dc501d0e7ec2e1586a258336c2f3a2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání